🇺🇸 FDA
Patent

US 11365189

Heterocyclic inhibitors of tyrosine kinase

granted A61PA61P35/04

Quick answer

US patent 11365189 (Heterocyclic inhibitors of tyrosine kinase) held by The Board of Regents of the University of Texas System expires Mon Jun 16 2042 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
The Board of Regents of the University of Texas System
Grant date
Tue Jun 21 2022 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Jun 16 2042 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
30
CPC classes
A61P, A61P35/04